Veronika Isaeva

Dr. Veronika Isaeva


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2026 in Molecules
Verified
Journal Article
Open access
PDF file
MTMaria Trestsova
Maria Trestsova
DADaria A. Andreeva
Daria A. Andreeva
Mikhail KiskinMikhail Kiskin
Mikhail Kiskin
MKMaria V Komelkova
Maria V Komelkova
PVPavel Vassiliev
Pavel Vassiliev
ASAlexey Sarapultsev
Alexey Sarapultsev
A light-promoted C–H/C–H coupling of imidazo[1,2-a]pyridines with 5-(hetero)aryl-1,2,5-oxadiazolo[3,4-b]pyrazines was developed using a heterogeneous oxidative photocatalytic system based on molecular oxygen, nanosized TiO2, and light irradiation. The method provides direct access to C3-heteroarylated imidazo[1,2-a]pyridines under metal-free conditions and expands the synthetic utility of electron-deficient oxadiazolopyrazine partners in the construction of biheteroaryl scaffolds. The synthesized compounds were evaluated computationally using a fully connected convolutional correlation neural network based on multiple-docking energy spectra, which prioritized the series as potential COX-1 and COX-2 ligands. To test this prioritization experimentally, all 18 compounds were screened in fluorometric COX-1 and COX-2 inhibitor assays at 1 µM. Compound 3f emerged as a strong preliminary COX-1 hit at 1 µM (86.64 ± 5.18% inhibition), whereas 3h and 3l showed weaker COX-1 inhibition. No compound showed high or moderate COX-2 inhibition at the screening concentration; only weak COX-2 inhibitory signals were observed for several derivatives. Thus, the combined synthetic, computational, and enzymatic data identify compound 3f as the main COX-1-skewed hit in this series and provide a basis for further dose–response, selectivity, and cell-based anti-inflammatory studies. It should also be noted that the COX-1 inhibition assay used ovine COX-1, whereas the computational models were built on human COX-1 and COX-2 structures; this species difference is an additional reason to treat the in silico–experimental comparison as approximate.

Verified
Journal Article
Open access
PDF file
MKMaria V Komelkova
Maria V Komelkova
SFStanislav Fedorov
Stanislav Fedorov
VIVeronika Isaeva
Veronika Isaeva
IUIrina Utepova
Irina Utepova
YGYulia Grigoreva
Yulia Grigoreva
ASAlexey Sarapultsev
Alexey Sarapultsev
Depression and stress-related disorders remain important targets for the development of new neuroactive compounds. We evaluated three imidazo[1,2-a]pyridine–[1,2,5]oxadiazolo[3,4-b]pyrazine derivatives, selected by a SERT-oriented computational screen, using chemical characterization, zebrafish embryo toxicity, larval and adult zebrafish behavioural assays, mouse behavioural HPLC, and qPCR experiments. AD19/UtIA-0167 had the highest computational consensus but showed greater embryo toxicity and no consistent advantage in adult zebrafish. AD20/UtIA-0108 showed a distinct larval locomotor profile, increased middle-zone occupancy after chronic exposure in stressed adult zebrafish, and was therefore examined in mice. Chronic AD20 increased latency to enter the dark compartment; whereas, time in the light compartment, open-field measures and forced-swim immobility were unchanged. HPLC and qPCR changes were region-specific and did not demonstrate direct SERT engagement. AD20 should therefore be regarded as an early neuroactive candidate from a SERT-oriented screen, not as a confirmed SERT inhibitor or antidepressant. Interpretation across species is limited by the duplicated zebrafish serotonin-transporter system, waterborne exposure and the limited scope of the mouse behavioural effect. Direct transporter assays, pharmacokinetic studies and independent behavioural replication are required.